Phenylbutazone: Target Organs and Levels of Evidence for TR-367
Toxicology and Carcinogenesis Studies of Phenylbutazone (CASRN 50-33-9) in F344/N Rats and B6C3F1 Mice (Gavage Studies)
Chemical (Study Title)
CASRN | Peer Review Date | Route/Exposure Levels | Study Laboratory |
|---|
Phenylbutazone
50-33-9 | 03/13/1989 | Gavage
R: 0, 50, 100, M: 0, 150, 300 MG/KG/50 PER GROUP | T.S.I. Mason Laboratories, Inc. |
Levels of Evidence
Male Rats: Equivocal Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Kidney Tubular Cell:
ADENOMA 0/50 0/49 3/50 OR CARCINOMA 0/50 1/49 0/50 COMBINED 0/50 1/49 3/50
|
| Non-Neoplastic Lesions | - KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; PAPILLA, NECROSIS 1/50 10/49 24/50; COLLECTING TUBULE, MINERALIZATION 5/50 10/49 35/50
|
Female Rats: Some Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Kidney Transitional Cell:
CARCINOMA 0/50 0/50 2/50
|
| May Have Been Related | - Kidney Tubular Cell:
ADENOMA (STEP SECTIONS) 0/50 3/50 1/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 0/50 4/50 1/50
|
| Non-Neoplastic Lesions | - KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; PAPILLA, NECROSIS 0/50 18/50 35/50; COLLECTING TUBULE, MINERALIZATION 3/50 31/50 46/50
|
Male Mice: Some Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Liver:
ADENOMA 8/50 12/50 24/50 OR CARCINOMA 8/50 4/50 11/50 COMBINED 16/50 14/50 31/50
|
Female Mice: No Evidence
